Hepatitis B Surface Antibody (HBsAb)
This biomarker measures the level of antibodies produced in response to the hepatitis B surface antigen, indicating immunity to hepatitis B virus.
HBsAb levels indicate immunity to hepatitis B virus.
Key facts at a glance
- Units
- mIU/mL
- Clinical utility
- diagnostic
- Result kind
- quantitative
- FDA-cleared
- Roche Anti-HBs, Abbott Anti-HBs, Siemens Anti-HBs
Hepatitis B Surface Antibody (HBsAb) is a blood test that detects antibodies produced by the immune system in response to the hepatitis B surface antigen (HBsAg). It is used to determine if a person has developed immunity to the hepatitis B virus, either through vaccination or previous infection.
The reference range for HBsAb is typically between 10–10000 mIU/mL. Levels above 10 mIU/mL generally indicate immunity, while levels below this threshold may suggest a need for vaccination or a booster shot.
This test is crucial for diagnosing past exposure to hepatitis B, assessing the effectiveness of vaccination, and guiding clinical decisions regarding patient care and prevention strategies.
Frequently asked questions
What does a positive HBsAb test mean?
What if my HBsAb levels are low?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy